Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

NXTCNXTC
28 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in NextCure, Inc.

CITADEL ADVISORS LLC previously held 0 shares of NXTC (NextCure, Inc.), worth $0 as of 2026-Q2.

Final Value

$0

Final Shares

0

Total Value Change

-$16.4M

Total Shares Change

-1.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$1.60
0
2026-Q1
New
15,292
-
$160,8720.0%$12.05
34
2025-Q3
Exited
0
-100.0%
$00.0%$5.79
0
2025-Q2
Decreased
58,845
-35.1%
$27,0690.0%$5.40
0
2025-Q1
Increased
90,643
+15.2%
$43,5360.0%$5.99
16
2024-Q4
Increased
78,678
+40.6%
$60,6610.0%$9.96
19
2024-Q3
Decreased
55,954
-80.6%
$76,6570.0%$16.56
0
2024-Q2
Increased
289,050
+17.8%
$459,5890.0%$19.08
28
2024-Q1
Decreased
245,476
-34.7%
$547,4110.0%$26.76
0
2023-Q4
Decreased
375,850
-14.3%
$428,4690.0%$13.68
0
2023-Q3
Increased
438,610
+11.5%
$565,8070.0%$15.48
27
2023-Q2
Decreased
393,263
-18.0%
$707,8730.0%$21.60
0
2023-Q1
Decreased
479,847
-8.1%
$710,1730.0%$17.88
0
2022-Q4
Increased
522,164
+10.1%
$736,2510.0%$16.92
27
2022-Q3
Increased
474,097
+20.5%
$1.3M0.0%$33.72
30
2022-Q2
Increased
393,366
+0.9%
$1.8M0.0%$58.08
26
2022-Q1
Decreased
389,989
-0.9%
$1.9M0.0%$59.40
0
2021-Q4
Decreased
393,636
-0.8%
$2.4M0.0%$73.92
0
2021-Q3
Decreased
396,715
-44.3%
$2.7M0.0%$81.96
0
2021-Q2
Decreased
711,624
-32.9%
$5.7M0.0%$96.48
0
2021-Q1
Decreased
1.1M
-1.3%
$10.6M0.0%$117.72
0
2020-Q4
Decreased
1.1M
-0.3%
$11.7M0.0%$133.20
0
2020-Q3
Increased
1.1M
+1866.9%
$9.5M0.0%$102.36
45
2020-Q2
Decreased
54,759
-34.4%
$1.2M0.0%$266.28
0
2020-Q1
Decreased
83,514
-89.5%
$3.1M0.0%$443.28
0
2019-Q4
Decreased
797,706
-15.3%
$44.9M0.0%$638.40
0
2019-Q3
Decreased
941,557
-13.9%
$29M0.0%$393.00
0
2019-Q2
New
1.1M
-
$16.4M0.0%$179.76
39

Other major holders of NXTC: ALLIANCEBERNSTEIN L.P., HHLR ADVISORS, LTD.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used